Future ART Costs
Approximately 6.6 million people were receiving anti-retroviral therapy (ART) in low- and middle-income countries at the end of 2010. At current survival rates most of these patients can expect to live another 20 years or more if they continue to receive treatment. Thus the scale-up of treatment today implies a long-term commitment to continue support well into the future. This website provides tools and analysis to improve understanding of the extent of that commitment and is organized around five key questions:
- What is the lifetime cost of one person starting on ART today?
- How many people will receive ART and what will be the future costs in low- and middle-income countries for selected parameters?
- What will be the impact of ART in terms of deaths prevented and new infections averted?
- How many people will be in need of ART but not receiving treatment?
- What funding is available for ART and how much more is needed?